As your browser does not support javascript you won't be able to use all the features of the website. We strongly recommend you to enable the javascript in your old browser's settings or download a new one.

UPDATE 2-FDA approves Amgen's injected immunotherapy for melanoma

Oct 27 (Reuters) - U.S. health regulators on Tuesday approved Amgen Inc's novel cancer immunotherapy for injection into melanoma lesions and lymph nodes of patients with the deadliest form of skin cancer that returns after initial surgery.

The drug, to be sold under the brand name Imlygic, is an engineered version of a herpes virus that kills cancer cells when injected directly into cancerous lesions on or under the skin, destroying them from the inside, while also priming the immune system to attack the disease.

The Food and Drug Administration said Imlygic, known chemically as talimogene laherparepvec, or T-Vec, is the first oncolytic virus therapy to be...